Cited by 574Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Efficacy and safety of degludec versus glargine in type 2 diabetes.

Open access

Marso, Steven P., McGuire, Darren K., Zinman, Bernard, Poulter, Neil R., Emerson, Scott S., Pieber, Thomas R., Pratley, Richard E., Haahr, Poul-Martin, Lange, Martin, Brown-Frandsen, Kirstine, Moses, Alan, Skibsted, Simon, Kvist, Kajsa, Buse, John B.·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1615692PMC PMC5731244

Open this paper in CoChat — free account

Abstract

BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS: We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial. The primary composite outcome in the time-to-event analysis was the first occurrence of an adjudicated major cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) with a prespecified noninferiority margin of 1.3. Adjudicated severe hypoglycemia, as defined by the American Diabetes Association, was the prespecified, multiplicity-adjusted secondary outcome. RESULTS: Of the patients who underwent randomization, 6509 (85.2%) had established cardiovascular disease, chronic kidney disease, or both. At baseline, the mean age was 65.0 years, the mean duration of diabetes was 16.4 years, and the mean (±SD) glycated hemoglobin level was 8.4±1.7%; 83.9% of the patients were receiving insulin. The primary outcome occurred in 325 patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferiority). At 24 months, the mean glycated hemoglobin level was 7.5±1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec group than in the glargine group (128±56 vs. 136±57 mg per deciliter, P<0.001). Prespecified adjudicated severe hypoglycemia occurred in 187 patients (4.9%) in the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 1.7 percentage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority). Rates of adverse events did not differ between the two groups. CONCLUSIONS: Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events. (Funded by Novo Nordisk and others; DEVOTE ClinicalTrials.gov number, NCT01959529 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1615692

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
(2013) · JAMA · doi:10.1001/jama.2013.281053 · Cited by 30,732
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471

Flagged first, then by citations

Show all 27 references

Research works printed but not linked: 2

2001, J Postgrad Med, 47, 199
Wysham C, 2016, Diabetologia, 59, S43. abstract

Sorted by citations

Items 301–400 of 572

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
Oya, J., Nakagami, T., Hasegawa, Y., Katamine, A., Kondo, Y., & Babazono, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13559 · Cited by 7
Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira : A real‐world, population‐based cohort study
Cowart, K., Gonzalez, R. V. L., & Carris, N. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14579 · Cited by 7
Insulin degludec overdose may lead to long‐lasting hypoglycaemia through its markedly prolonged half‐life
Uchida, J., Oikawa, Y., Katsuki, T., Takeda, H., Shimada, A., & Kawai, T. (2017) · Diabetic Medicine · doi:10.1111/dme.13557 · Cited by 7
Análisis de las características de los pacientes con diabetes mellitus que consultan por hipoglucemia en el servicio de urgencias de un hospital terciario
Corchuelo, J. C., Guerrero‐Pérez, F., de la Jordana, P. G.-S., & Pérez-Maraver, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.06.013 · Cited by 8
Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials
Rados, D. R. V., Viecceli, C., Pinto, L. C. F., Gerchman, F., Leitão, C. B., & Gross, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-69738-w · Cited by 6
Considerations for Insulin-Treated Type 2 Diabetes Patients During Hospitalization: A Narrative Review of What We Need to Know in the Age of Second-Generation Basal Insulin Analogs
D’Souza, S., & Kruger, D. F. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00920-z · Cited by 7
Basal insulin analogues in people with diabetes and chronic kidney disease
Jiménez, D. L., Miramontes‐González, J. P., Márquez‐López, L., Astudillo‐Martín, F., Beltrán, L. M., Obregón, F. M., & Martín, J. E. (2021) · Diabetic Medicine · doi:10.1111/dme.14679 · Cited by 7
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 9
Resolution on the results of the first working meeting of the scientific advisory board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»
Antsiferov, M. B., Galstyan, G. R., Zilov, A. V., Mayorov, A. Y., Markova, T. N., Demidov, N. A. D., Koteshkova, O. M. K., Лаптев, Д. Н., & Vitebskaya, A. V. (2019) · Diabetes Mellitus · doi:10.14341/dm10227 · Cited by 8
Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study
Olmo-García, M. I. D., Hervás, D., Caudet-Esteban, J., Martín-Portugués, A. B., Rubio, A. C., Vives, M. Á. A., Catalá-Gregori, A. I., Martínez, M. P., & Merino-Torres, J. F. (2020) · Journal of International Medical Research · doi:10.1177/0300060520926063 · Cited by 7
Cardiovascular Disease in Diabetes
Piché, M., & Poirier, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95793-3 · Cited by 7
Transforming disease management: The clinical benefits of long-acting injectable drug delivery systems
Rathore, G., & Singh, R. P. (2025) · Intelligent Hospital · doi:10.1016/j.inhs.2025.100001 · Cited by 8
Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials
Dehghani, M., Sadeghi, M., Barzkar, F., Maghsoomi, Z., Janani, L., Motevalian, S. A., Loke, Y. K., Ismail‐Beigi, F., Baradaran, H. R., & Khamseh, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1286827 · Cited by 9
Impact on guidelines: The general practitioner point of view
Cos, X., Seidu, S., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. K. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108091 · Cited by 6
The association of long‐acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population‐based cohort study
Brunetti, V. C., Yu, O. H. Y., Platt, R. W., & Filion, K. B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14802 · Cited by 6
Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US)
Black, J. E., Harris, S. B., Ryan, B. L., Zou, G., & Ratzki‐Leewing, A. A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01423-3 · Cited by 7
Therapy of Type 2 Diabetes
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 5
Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents
Saxon, D. R., Rasouli, N., & Eckel, R. H. (2018) · Drugs · doi:10.1007/s40265-017-0857-3 · Cited by 6
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL
Philis‐Tsimikas, A., Lane, W. S., Pedersen‐Bjergaard, U., Wysham, C., Bardtrum, L., Østoft, S. H., & Heller, S. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13954 · Cited by 6
Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study
Taki, K., Koyanagi, M., Nagaoka, S., & Shingaki, T. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1834374 · Cited by 6
Clinical implications of cardiovascular outcome trials in type 2 diabetes
Mellbin, L., Wang, A., & Rydén, L. (2019) · Herz · doi:10.1007/s00059-019-4789-4 · Cited by 6
GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study
Tentolouris, A., Ntanasis‐Stathopoulos, I., Filippatos, C., Terpos, E., Kastritis, E., Duque, E. R., Dimopoulos, M. A., Gavriatopoulou, M., & Briasoulis, Α. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70140 · Cited by 6
Préparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial
Tang, C., Su, R., Wan, L., Zhu, M., Pu, J., Hao, C., Zhao, J., He, A., Xie, T., Li, Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16250 · Cited by 6
Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2019)
Clodi, M., Saely, C. H., Hoppichler, F., Resl, M., Steinwender, C., Stingl, H., Wascher, T. C., Winhofer-Stöckl, Y., & Sourij, H. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1488-3 · Cited by 5
Positionspapier Herzinsuffizienz und Diabetes
Schütt, K. S., Aberle, J., Bauersachs, J. K., Birkenfeld, A. L., Frantz, S., Ganz, M., Jacob, S., Kellerer, M., Leschke, M., Liebetrau, C., et al. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1867-3026 · Cited by 5
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
Katsiki, N., Kazakos, K., & Triposkiadis, F. K. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2143263 · Cited by 6
Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023)
Clodi, M., Saely, C. H., Hoppichler, F., Resl, M., Steinwender, C., Stingl, H., Wascher, T. C., Winhofer, Y., & Sourij, H. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02183-7 · Cited by 5
Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel
Tabák, Á. G., Kempler, P., Guja, C., Eldor, R., Haluzı́k, M., Klupa, T., Παπάνας, Ν., Stoian, A. P., & Mankovsky, B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01556-z · Cited by 5
Guía de práctica clínica sobre detección y manejo de la enfermedad renal diabética: documento de consenso de la Sociedad Española de Nefrología
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicechea, M., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.11.002 · Cited by 5
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 6
Adaptive-TMLE for the average treatment effect based on randomized controlled trial augmented with real-world data
van der Laan, M. J., Qiu, S., Tarp, J. M., & van der Laan, L. W. P. (2026) · Journal of Causal Inference · doi:10.1515/jci-2024-0025 · Cited by 5
Different Insulin Initiation Regimens in Patients with Type 2 Diabetes - A Review Article
Mudassir, A. M., Thida, A. K., Meela, A., Eligar, V. S., Js, D., & Madelein, Y. (2018) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410083 · Cited by 5
Perspectives on diabetes mortality as the result of residual confounding and reverse causality by common disease
Thuesen, A. C. B., & Vaag, A. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13238 · Cited by 5
Cardiovascular outcome trials of glucose-lowering therapies
Khunti, K. K., Davies, M. J., & Seidu, S. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1763796 · Cited by 5
Co-Formulations as the First Injectable in Type 2 Diabetes: A Review of Efficacy, Safety, and Implications in Clinical Practice
John, M., Gopinath, D., & Oommen, T. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000509045 · Cited by 5
Diabetes mellitus y riesgo cardiovascular: actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2021)
Arrieta, F., Pedro‐Botet, J., Iglesias, P., Obaya, J. C., Montánez, L., Maldonado, G. F., Becerra, A., Navarro, J., Perez, J. C., Petrecca, R., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.05.002 · Cited by 15
Therapie des Typ-2-Diabetes
Landgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0459-7 · Cited by 5
Type 2 diabetes in youth: Rationale for use of off‐label antidiabetic agents
Kelsey, M. M., Zeitler, P. S., Nadeau, K. J., & SHAH, A. S. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13350 · Cited by 7
Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
Gerstein, H. C., & Shah, R. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.003 · Cited by 6
Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy
Langer, J., Wolden, M. L., Shimoda, S., Sato, M., & Araki, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0635-1 · Cited by 5
Expert Group Recommendations on Detection and Management of Hypoglycemia in Routine Clinical Practice in Insulin Treated Patients with Diabetes.
Singh, A. K., Talwalkar, P., Ahluwalia, A. I., Modi, K. D., & Saboo, B. (2018) · PubMed · Cited by 5
Efecto de terapias farmacológicas para el control glicémico en pacientes con diabetes mellitus tipo 2 en los desenlaces vasculares
Vargas, J. M., Rico-Fontalvo, J. E., Enrique Melgarejo, R., Castillo, G. A., Rincón, A. R., Gómez, A. M., Rojas, S. M., & Ibatá, L. (2020) · Revista Colombiana de Nefrología · doi:10.22265/acnef.7.1.372 · Cited by 9
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
Lin, Y., Huang, Y., Wu, Y., Lin, C.-W., Chen, P.-C., Chang, C. J., Hsieh, S., Sun, J., Chen, S., & Lin, C.-H. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0378-6 · Cited by 5
Heart Failure in Diabetes Mellitus: An Updated Review
Sohrabi, C., Saberwal, B., Lim, W. Y., Tousoulis, D., Ahsan, S., & Παπαγεωργίου, Ν. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118091659 · Cited by 5
Revisiting NPH Insulin for Type 2 Diabetes
Crowley, M. J., & Maciejewski, M. L. (2018) · JAMA · doi:10.1001/jama.2018.8033 · Cited by 5
Design of a novel long-acting insulin analogs by acetylation modification and compared with insulin Icodec
Yu, M., Zhang, C., Xu, H., Dong, Y., Zhu, H., Xia, C., & Feng, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-94014-0 · Cited by 5
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
BAJAJ, H. S., & Zinman, B. (2018) · Physiology · doi:10.1152/physiol.00004.2018 · Cited by 4
Self-citation
The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review
Sloan, L. A., CHENG, A. Y. Y., Escalada, J., Haluzı́k, M., & Mauricio, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15425 · Cited by 4
Age‐ and gender‐adjusted estimated glomerular filtration rate definition reveals hyperfiltration as a risk factor for renal function deterioration in type 2 diabetes
Wen, W., Lee, Y., Hwu, D., & Chang, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15465 · Cited by 4
Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes
Ji, L., & Chen, Y. (2024) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2024.07.007 · Cited by 5
European Society of Cardiology 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12608 · Cited by 4
Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
Chang, C., & Chuang, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12776 · Cited by 4
Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study
Home, P. D., Calvi-Gries, F., Blonde, L., Pilorget, V., Berlingieri, J., & Freemantle, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13179 · Cited by 4
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials
Rose, L., Kadowaki, T., Pieber, T. R., Buchholtz, K., Ekelund, M., Gorst‐Rasmussen, A., & Philis‐Tsimikas, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0608-4 · Cited by 4
Self-citation
Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)
Pollock, R. F., Heller, S. R., Pieber, T. R., Woo, V. C., Gundgaard, J., Hallén, N., Luckevich, M., Tutkunkardas, D., Zinman, B., & On Behalf of the DEVOTE Study Group (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13730 · Cited by 4
Self-citation
Effectiveness and safety of insulin glargine Gla-300 in insulin-naïve type 2 diabetes subjects in a real-life setting—the GOAL_RO trial
for the GOAL_RO Study Group, Stegaru, D., Nicodim, S., Vladu, D., Guțu, O., Onaca, A. G., Pîrvu, F., Moise, M., & Guja, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4533 · Cited by 4
Quality of life in patients with type 2 diabetes after switching to insulin degludec: results from a cross-sectional survey
Uzoigwe, C., Radin, M. S., Hamersky, C. M., DeKoven, M., Holt, C., Karkare, S. U., & Polonsky, W. H. (2021) · Quality of Life Research · doi:10.1007/s11136-020-02753-6 · Cited by 4
Hundert Jahre – Insulin bleibt aktuell und notwendig
Landgraf, R., & Aberle, J. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1386-0011 · Cited by 4
Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study
Harris, S. B., Ajala, O., Bari, B., Liutkus, J., Hahn, J., Martyn, O., & Zwicker, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01063-5 · Cited by 4
One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)
Kesavadev, J., Murthy, L. S., Chaudhury, T., Yalamanchi, S. R., Giri, J., Gupta, S., Phatak, S., Modi, K. D., Chatterjee, S., Manjunath, A., et al. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100184 · Cited by 4
Therapie des Typ-2-Diabetes
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 4
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
Effect of low dose allopurinol on glycemic control and glycemic variability in patients with type 2 diabetes mellitus: A cross-sectional study
Alem, M. M. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11549 · Cited by 4
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial
Rosenstock, J., Kolkailah, A. A., McGuire, D. K., Espeland, M. A., Mattheus, M., Pfarr, E., Lund, S. S., Marx, N., & the CAROLINA Investigators (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14991 · Cited by 4
Self-citation
Long-Term Benefits of an Integrated Continuous Glucose Monitoring and Insulin Pump System for Emergency Admissions, Hospitalization, and Metabolic Control in a Cohort of People With Diabetes: Retrospective Cohort Study
Omeara, M., Acuña, J. C. M., & Uribe, A. (2023) · JMIR Diabetes · doi:10.2196/46880 · Cited by 4
Diabetes and Ramadan fasting
Ahmedani, M. Y., El-Sayed, A. A., & Yousuf, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22106-4.00031-0 · Cited by 4
Clinical Challenges With Concentrated Insulins: Setting the Record Straight
Brusko, C., Taylor, A. D., Jackson, J. A., & Bunck, M. C. M. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0008 · Cited by 4
Quantitative contrast-enhanced ultrasound of renal perfusion: a technology for the assessment of early diabetic nephropathy in cynomolgus macaques with type 2 diabetes mellitus
Luo, J., Chen, J., Sun, Y., Zhou, H., Xu, K., Huang, F., & Huang, P. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-01908-5 · Cited by 4
Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
Tentolouris, N., Knudsen, S. T., Lapolla, A., Wolden, M. L., Haldrup, S., & Schultes, B. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00916-7 · Cited by 4
Consensus Statement on Use of Ambulatory Glucose Profile in Patients with Type 2 Diabetes Mellitus Receiving Oral Antidiabetic Drugs.
Unnikrishnan, A., Saboo, B., Joshi, S., Kesavadev, J., Makkar, B. M., Agarwal, S., Aravind, S. R., Seshadri, K., Chawla, M. S., Deshpande, N., et al. (2019) · PubMed · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 4
Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée
Monnier, L., Colette, C., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00178-4 · Cited by 4
Conceptos Actuales de la Terapia Con Insulina.
Montero, G. J., Barakat, M. V., & Solórzano, M. L. C. (2022) · Revista Ciencia y Salud Integrando conocimientos · doi:10.34192/cienciaysalud.v6i3.416 · Cited by 4
Re-examining insulin compared to non-insulin therapies for type 2 diabetes: when in the disease trajectory is insulin preferable?
Mishriky, B. M., Cummings, D. M., Tanenberg, R. J., & Pories, W. J. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1533381 · Cited by 5
Diagnose, Prävention und Behandlung kardiovaskulärer Ereignisse bei Menschen mit Diabetes und Prädiabetes
Koskinas, K. C., Melmer, A., Steiner, N., Gübeli, A., Wilhelm, M., & Laimer, M. W. (2021) · Praxis · doi:10.1024/1661-8157/a003589 · Cited by 4
Efficacy and Cardiovascular Safety of Antidiabetic Medications
Pappachan, J. M. (2021) · Current Drug Safety · doi:10.2174/1574886316666210112153429 · Cited by 4
Diabetes in pregnancy and major new advances in diabetes care using long-acting and ultralong-acting insulins
Drummond, R. F., Seif, K. E., Higgs, A. J., & Reece, E. A. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.08.088 · Cited by 3
RSSDI guidelines for management of type 2 diabetes mellitus in older adults
Jagadeesha, A., Viswanathan, V., Agarwal, S., Maheshwari, A., Virmani, A. K., Nagendra, L., Amarnath, A., Chawla, M. S., Jethwani, P., Parikh, R. M., et al. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01613-8 · Cited by 4
Association of insulin use with LV remodeling and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: assessed by cardiac MRI
Shi, K., Zhang, G., Fu, H., Huang, S., Xu, H., Gao, Y., Shi, R., Yan, W., Qian, W., Li, Y., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01944-y · Cited by 3
Clinical Use of IDegLira: Initiation to Titration After Basal Insulin
Warren, M., & Steel, D. (2019) · Clinical Diabetes · doi:10.2337/cd19-0015 · Cited by 3
Insulin degludec allows for better glycaemic control with a lower risk of hypoglycaemia in patients with chronic kidney disease and type 2 diabetes
de Lucas, M. D. G., Avilés, B., Rivas‐Ruiz, F., & Olalla, J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108094 · Cited by 3
Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India
WANGNOO, S. K., Shunmugavelu, M., Reddy, S. V. B., Negalur, V. B., Godbole, S. V., Dhandhania, V. K., Krishna, N., & Gaurav, K. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100102 · Cited by 3
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
Harris, S. B., Parente, E. B., & Karalliedde, J. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01247-7 · Cited by 3
Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus
Sethi, B. K., Unnikrishnan, A., Ayyar, V. S., Jabbar, P. K., Ganguly, K. K., Bhandari, S., Rastogi, A., Mukherjee, R., Sundaram, V., & Asirvatham, A. R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01284-2 · Cited by 3
Positionspapier Herzinsuffizienz und Diabetes
Schütt, K. S., Aberle, J., Bauersachs, J. K., Birkenfeld, A. L., Frantz, S., Ganz, M., Jacob, S., Kellerer, M., Leschke, M., Liebetrau, C., et al. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00562-4 · Cited by 3
Effect of dipeptidyl peptidase‐4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus
Choi, Y., Ko, S., Chang, K., Yoo, K., & Ihm, S. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13449 · Cited by 3
Documento de consenso sobre el manejo de la diabetes tipo 2 y la insuficiencia cardíaca: Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC)
Romero, A., Saldarriaga, C., Ramos, C. E., Quesada, D., Chazzin, G., Fernández, F. N. G., Pow-Chon-Long, F., Alarco, W., Hurtado, P. E., Magaña, J. A., et al. (2023) · Archivos de cardiología de México · doi:10.24875/acm.23000059 · Cited by 3
Primary Care and Diabetes Technologies and Treatments
Martens, T. W., Simonson, G. D., Carlson, A. L., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.2510 · Cited by 3
Insulin Degludec in People with Type 2 Diabetes in China: A Non-interventional, Retrospective Chart Review Study (CN-TREAT)
Wang, W., Chang, X., Lehrskov, L. L., Li, L., Nordentoft, M., Quan, J., Sha, Y., Zhong, X., Yang, C., & Zhu, D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01533-6 · Cited by 3
Implications of cardiovascular outcome trials with injectable antidiabetic agents
Pratley, R. E. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12792 · Cited by 3
Self-citation
Analysis of the characteristics of patients with diabetes mellitus who attend a tertiary hospital emergency department for a hypoglycemic event
Corchuelo, J. C., Guerrero‐Pérez, F., de la Jordana, P. G.-S., & Pérez-Maraver, M. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.06.007 · Cited by 4
How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?
Home, P. D. (2020) · Diabetes Care · doi:10.2337/dci19-0056 · Cited by 3
Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey
Svensson, A., Ekelund, J., Miftaraj, M., & Eliasson, B. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00767-4 · Cited by 3
Identification of the Inappropriate Clinical Actions (DON'T) to Improve the Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy
Leto, G., Barchetta, I., Candia, L. D., Magotti, M. G., Cianciullo, M., Manti, R., Negri, C., Cimino, V., Dodesini, A. R., Zerella, F., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01137-4 · Cited by 3
The impact of glucose-lowering medications on cardiovascular disease
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2017) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000139 · Cited by 3
Impact des nouvelles classes d’antidiabétiques sur le risque cardiovasculaire dans le diabète de type 2
Bauduceau, B., & Monnier, L. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30023-9 · Cited by 3
Resolution on the results of the first working meeting of the Scientific Advisory Board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»
Antsiferov, M. B., Galstyan, G. R., Zilov, A. V., Mayorov, A. Y., Markova, T. N., Demidov, N. A. D., Koteshkova, O. M. K., Лаптев, Д. Н., Vitebskaya, A. V., Alekseeva, Y. G., et al. (2019) · Problems of Endocrinology · doi:10.14341/probl10197 · Cited by 3
Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
Pieber, T. R., Bardtrum, L., Isendahl, J., Wagner, L., & Nishimura, R. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00755-3 · Cited by 3
Self-citation

Authors: Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., Moses, A., Skibsted, S., Kvist, K., & Buse, J. B.
Affiliations: Mount Sinai Hospital (CA)
University of North Carolina at Chapel Hill (US)
ORCID: McGuire, Darren K.
Zinman, Bernard
Poulter, Neil R.
Emerson, Scott S.
Pieber, Thomas R.
Pratley, Richard E.
Lange, Martin
Kvist, Kajsa
Buse, John B.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-08-24
Volume: 377
Issue: 8
Pages: 723-732
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1615692
PMC: PMC5731244
OpenAlex: W2625031949
Cited by: 574
References: 27
Citations by year: 2026: 20 · 2025: 16 · 2024: 41 · 2023: 43 · 2022: 56 · 2021: 61 · 2020: 81 · 2019: 104 · 2018: 100 · 2017: 50
FWCI: 72.47
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Acibadem University Open Access Repository (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
Versus Arthritis (20639, 18475)
National Institutes of Health (UL1TR001111, UL1TR002489)
National Institute of Diabetes and Digestive and Kidney Diseases (T35DK060444, P30DK020541)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: insulin degludec, insulin glargine, type 2 diabetes, basal insulin, cardiovascular safety, major adverse cardiovascular events, severe hypoglycemia, HbA1c, fasting blood glucose, non-inferiority, cardiovascular disease, chronic kidney disease, glycemic variability, insulin duration of action
MeSH terms: Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Incidence, Insulin, Long-Acting, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and safety of degludec versus glargine in type 2 diabetes.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks